NIDDM患者无症状性心或脑缺血时血中TNF—α,t—PA及PAI的改变

为了解无症状性心或脑缺血的非胰岛素依赖型糖尿病患者的血中肿瘤坏死因子－α（ＴＮＦ－α）及纤溶活性的变化，我们观察了２０例正常人，２５例ＮＩＤＤＭ伴无症状性心或脑缺血患者、１８例ＮＴＤＤＭ不伴无症状性心或脑缺血中ＴＮＦ－α水平，组织型纤溶酶原激活剂活性和ＰＡ抑制物活性的改变。结果显示：ＴＮＦ－α，ＰＡＩ和ＮＩＤＤＭ伴无症状缺血患者最高，而ｔ－ＰＡ最低，表明ＴＮＦ－α水平升高及纤溶活性降低参与了ＮＩＤ

Changes of serum TNF-alpha level, t-PA activivty and PAI activity in patients with silent myocardial ischemia or silent cerebral ischemia]

Tumor necrosis factor-alpha (TNF-alpha) level, tissue-typed plasminogen activator(t-PA) activity and PA inhibitor (PAI) activity were determined in three groups: (1) 25 NIDDM patients with silent myocardial ischemia (SMI) or silent cerebral ischemia (SCI); (2) 18NIDDM patients without SMI or SCI; (3) 20 age-matched normal controls. Diagnosis of SMI or SCI was based on the finding of ischemic evidence by SPECT of myocardiotomograph or cerebrotomograph. All patients ECG and blood pressure were normal, and they had no history of clinical symptoms and signs of MI or CI. The result showed that the TNF-alpha level and PAI activity in the ischemia group were the highest and the t-PA activity in the ischemia group was the lowest, as compared with those in the other two groups respectively. It suggests that in NIDDM patients who have high TNF-alpha, high PAI activity, low t-PA, and even no symptoms and signs of MI or CI, anticoagulant therapy might be useful to prevent the progression of diabetic macroangiopathies.